<--- Back to Details
First PageDocument Content
Biology / Cell biology / Anatomy / Cellular processes / Vesicles / NPC1 / Cardiology / Lipoproteins / Cholesterol / Lysosomal storage disease / LAMP1 / Low-density lipoprotein
Date: 2015-11-17 16:51:10
Biology
Cell biology
Anatomy
Cellular processes
Vesicles
NPC1
Cardiology
Lipoproteins
Cholesterol
Lysosomal storage disease
LAMP1
Low-density lipoprotein

CrossMark_Color_flat+click

Add to Reading List

Source URL: pfeffer.stanford.edu

Download Document from Source Website

File Size: 1,05 MB

Share Document on Facebook

Similar Documents

Medicine / Health / Clinical medicine / Rare diseases / Porphyrias / Lysosomal storage diseases / RTT / Erythropoietic protoporphyria / Glycogen storage disease type II / Disease

How one patient with a rare disease coped with his genetic disorder

DocID: 1r9mW - View Document

Biology / Cell biology / Anatomy / Cellular processes / Vesicles / NPC1 / Cardiology / Lipoproteins / Cholesterol / Lysosomal storage disease / LAMP1 / Low-density lipoprotein

CrossMark_Color_flat+click

DocID: 1r0lC - View Document

What is HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive

DocID: 1lIxr - View Document

Mucopolysaccharidosis / Hunter syndrome / Hurler syndrome / Morquio syndrome / Sanfilippo syndrome / Maroteaux–Lamy syndrome / Genetic disorder / Lysosomal storage disease / Sly syndrome / Health / Syndromes / Rare diseases

MUCOPOLYSACCHARIDOSES Rare Diseases Unit of the Finnish Association of People with Physical Disabilities Support for this guide was provided by Genzyme.

DocID: 1fJSQ - View Document

Genetic genealogy / BioMarin Pharmaceutical / Glycogen storage disease type II / Acid alpha-glucosidase / Lysosomal storage disease / Mucopolysaccharidosis / Alglucosidase alfa / Neuronal ceroid lipofuscinosis / Tetrahydrobiopterin / Health / Rare diseases / Medicine

May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

DocID: 1aiEg - View Document